Cholecalciferol for prophylaxis against antituberculosis therapy-induced liver disorders among naïve patients with pulmonary tuberculosis: A randomized, comparative study
Hasanain AFA, Zayed AAH, Mahdy RE, Nafee AMA
International journal of mycobacteriology · 11 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-01-01 · Int J Mycobacteriol · vol. 6 · número 2 · pág. 149
- Editorial
- Elsevier BV
- Citado
- 13 citas · más que el 78% de estudios similares · 1.1× el promedio de su campo
- Referencias
- 35 trabajos
- Acceso
- Acceso abierto (publicación gratuita) · CC-BY-NC-SA
- Áreas de investigación
- Drug-Induced Hepatotoxicity and Protection · Tuberculosis Research and Epidemiology · Hepatitis C virus research
- Palabras clave
- Medicine, Internal medicine, Gastroenterology, Incidence (geometry), Adverse effect, Tuberculosis, Cholecalciferol, vitamin D deficiency, Population, Vitamin D and neurology, Pathology
- MeSH
- liver, humans, tuberculosis, pulmonary, cholecalciferol, antitubercular agents, prospective studies, adult, middle aged, female, male, young adult, chemical and drug induced liver injury
4 autores
- AhmadFarooq Alsayed Hasanain🇪🇬 · autor de correspondenciaAssiut University
- AliAbdel-Azeem Hasan Zayed🇪🇬Assiut University
- ReemEzzat Mahdy🇪🇬Assiut University
- AmanyMohamed Adawi Nafee🇪🇬Assiut University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Patients in countries endemic for chronic viral hepatitis are more vulnerable to antituberculosis therapy-induced liver disorders (ATT-LDs). The aim of this study was to explore the role of cholecalciferol in prophylaxis against ATT-LD among patients with pulmonary tuberculosis (TB) receiving ATT.
Material and methods
We conducted a hospital-based, prospective, randomized, comparative study which included 300 consecutive, naïve patients with pulmonary TB eligible for ATT. The patients were randomly allocated to Group A (150 patients who received ATT) and Group B (150 patients who received ATT with cholecalciferol) who had clinical evaluation, laboratory investigations, and imaging studies. Statistical analysis used student's t-test and Chi-square test were used as appropriate to compare the variables between the study groups.
Results
The study population mean age was 35.6 ± 15.3 years. The overall incidence rate of ATT-LD among the study population was 9.3%; the incidence rate was significantly higher among Group A patients compared to those of Group B (13.3 vs. 5.3%;P = 0.001). The onset of ATT-LD was significantly earlier among patients of Group A compared to those of Group B (31.4 vs. 58.7 days,P = 0.027), while the duration of ATT-LD was significantly longer among patients of Group A compared to those of Group B (34.8 vs. 16.9 days,P = 0.009). No adverse effects related to cholecalciferol use were observed.
Conclusions
Adjuvant cholecalciferol supplementation may be protective against ATT-LD without extra adverse effects. Before recommending the routine use of cholecalciferol supplementation for prevention of ATT-LD, larger scale studies are recommended.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.